Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...

Pharmacovigilance

Pharmacovigilance

Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...

Hazard Ratio

Hazard Ratio

The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial evaluating a...

Bioavailability Study Design: Healthy Subjects Versus Patients

Bioavailability Study Design: Healthy Subjects Versus Patients

Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...

Clinical Trials

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...

Study Designs in Epidemiology

Study Designs in Epidemiology

Epidemiological study designs are fundamental tools for investigating the distribution, determinants, and control of health conditions in populations. They help researchers understand the relationships between exposures and outcomes, and they broadly fall into two categories: "observational" and "experimental" studies.
Observational studies are those where the researcher does not intervene but rather observes natural variations. They include cross-sectional, cohort, and case-control studies.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Toward Evidence Synthesis of Adverse Events in Imbalanced Time-to-Event Data.

Journal of evidence-based medicine·2026

Same author

Mindfulness-Based Group Medical Visits for Persons With Chronic Low Back Pain: A Randomized Clinical Trial.

JAMA internal medicine·2026

Same author

Layers of complexity: a directed content analysis of implementation determinants for integrative group medical visits for patients with chronic pain in safety-net primary care.

BMC primary care·2026

Same author

Rarely reported cases of hepatotoxicity associated with turmeric- and curcuminoid-containing dietary supplements: a comprehensive review by USP.

Pharmaceutical biology·2026

Same author

Mandela Yoga Group Medical Visit: A Culturally Resonant Public Health Intervention for Diverse Communities With Chronic Medical Conditions.

American journal of public health·2026

Same author

SPIRIT 2025 statement: updated guideline for protocols of randomised trials.

Lancet (London, England)·2026

Search research articles

Related Experiment Video

Updated: May 31, 2026

Electroencephalographic, Heart Rate, and Galvanic Skin Response Assessment for an Advertising Perception Study: Application to Antismoking Public Service Announcements

Electroencephalographic, Heart Rate, and Galvanic Skin Response Assessment for an Advertising Perception Study: Application to Antismoking Public Service Announcements

Published on: August 28, 2017

A descriptive study evaluating Health Canada's risk communications.

Justin Bateman¹, Theresa L Charrois, Paula Gardiner

¹CARE Program-Department of Pediatrics, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alberta, Canada.

Pharmacoepidemiology and Drug Safety

|June 22, 2011

Summary

Health Canada issued similar numbers of risk communications (RCs) for natural health products (NHPs) and therapeutic products, but NHPs were more often associated with potential harm from contamination, while therapeutic products involved actual harms.

More Related Videos

High Content Screening Analysis to Evaluate the Toxicological Effects of Harmful and Potentially Harmful Constituents (HPHC)

High Content Screening Analysis to Evaluate the Toxicological Effects of Harmful and Potentially Harmful Constituents (HPHC)

Published on: May 10, 2016

Practical Methodology of Cognitive Tasks Within a Navigational Assessment

Practical Methodology of Cognitive Tasks Within a Navigational Assessment

Published on: June 1, 2015

Related Experiment Videos

Last Updated: May 31, 2026

Electroencephalographic, Heart Rate, and Galvanic Skin Response Assessment for an Advertising Perception Study: Application to Antismoking Public Service Announcements

Electroencephalographic, Heart Rate, and Galvanic Skin Response Assessment for an Advertising Perception Study: Application to Antismoking Public Service Announcements

Published on: August 28, 2017

High Content Screening Analysis to Evaluate the Toxicological Effects of Harmful and Potentially Harmful Constituents (HPHC)

High Content Screening Analysis to Evaluate the Toxicological Effects of Harmful and Potentially Harmful Constituents (HPHC)

Published on: May 10, 2016

Practical Methodology of Cognitive Tasks Within a Navigational Assessment

Practical Methodology of Cognitive Tasks Within a Navigational Assessment

Published on: June 1, 2015

Area of Science:

Pharmacovigilance
Regulatory Science
Public Health

Background:

Natural health products (NHPs) and therapeutic products undergo regulatory oversight.
Risk communications (RCs) are crucial for informing stakeholders about product-related harms.
Assessing differences in RCs for NHPs versus therapeutic products is important for consumer safety.

Purpose of the Study:

To compare Health Canada's risk communications (RCs) for natural health products (NHPs) and therapeutic products.
To identify differences in the nature, origin, and association of harms reported for NHPs and therapeutic products.

Main Methods:

A descriptive study evaluating RCs issued by Health Canada in 2006.
Independent evaluation of RCs by two investigators for harm characteristics, origin, and association.
Adjudication by a third reviewer for disagreements.

Main Results:

Health Canada issued 42 RCs for NHPs and 42 for therapeutic products.
NHP RCs predominantly cited potential harm (86%) from contamination/adulteration, unlike therapeutic product RCs (69% actual harms).
NHP RCs showed a higher degree of association with harm and originated from foreign sources/Health Canada, whereas therapeutic product RCs often came from drug manufacturers.

Conclusions:

Significant differences exist in Health Canada's risk communications for NHPs compared to therapeutic products.
Standardized formats for risk communications are recommended to ensure consistent information dissemination.